Hilde Hukkelberg
Direktor/Vorstandsmitglied bei SKAGEN AS
Profil
Hilde Hukkelberg currently works at Cytovation AS, as Independent Director from 2022 and SKAGEN AS, as Director from 2019.
Aktive Positionen von Hilde Hukkelberg
Unternehmen | Position | Beginn |
---|---|---|
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | Direktor/Vorstandsmitglied | 01.03.2019 |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Direktor/Vorstandsmitglied | 15.09.2022 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | Finance |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Commercial Services |